Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

By Ludwig Burger FRANKFURT (Reuters) -Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on ...

Not long after Basel, Switzerland, was selected as the next host of the annual Eurovision Song Contest, hometown pharma ...

Novartis’ 2.7 billion euro ($2.9 billion) gamble on MorphoSys has hit turbulence. | Novartis’ 2.7 billion euro gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has ...

The drug is now on the market in several EU countries, however, its price (around $42,500 in the US, which translates to just ...

With their headquarters in next year’s Host City, it’s great to have Novartis, a global leader in healthcare, supporting the ...

The global health landscape is bustling with updates. Romania reports bird flu, Coya Therapeutics reveals positive ...